Endophthalmitis Prophylaxis Failures in Patients Injected With Intracameral Antibiotic During Cataract Surgery.
Anterior Chamber
/ drug effects
Anti-Bacterial Agents
/ therapeutic use
Antibiotic Prophylaxis
Bacteria
/ isolation & purification
Cefuroxime
/ therapeutic use
Endophthalmitis
/ diagnosis
Eye Infections, Bacterial
/ diagnosis
Female
Humans
Injections, Intraocular
Lens Implantation, Intraocular
Male
Middle Aged
Moxifloxacin
/ therapeutic use
Phacoemulsification
Retrospective Studies
Treatment Failure
Journal
American journal of ophthalmology
ISSN: 1879-1891
Titre abrégé: Am J Ophthalmol
Pays: United States
ID NLM: 0370500
Informations de publication
Date de publication:
07 2021
07 2021
Historique:
received:
20
10
2020
revised:
06
02
2021
accepted:
06
02
2021
pubmed:
12
2
2021
medline:
24
7
2021
entrez:
11
2
2021
Statut:
ppublish
Résumé
To estimate the association of cefuroxime and moxifloxacin in relation to the occurrence of endophthalmitis following phacoemulsification cataract surgery. Retrospective clinical cohort study. We studied patients with noncomplex phacoemulsification cataract surgery in Kaiser Permanente Northern California during 2014-2019. Data were obtained for acute, postoperative endophthalmitis within 90 days of phacoemulsification, including culture and antibiogram results, intracameral and topical antibiotic agent, and dose. In a post hoc analysis, we also examined preoperative anterior chamber depth (ACD) and postoperative anterior chamber volume (ACV). Of 216,141 surgeries, endophthalmitis occurred in 0.020% of moxifloxacin-injected eyes and 0.013% of cefuroxime eyes (relative risk 1.62 with 95% CI 0.82-3.20, P = .16). Of the 34 (0.016%) cases of endophthalmitis, cefuroxime 1 mg was injected into 13 eyes and moxifloxacin 0.1% into 21 eyes. Organisms with antibiograms were identified in 12 (35%) cases. Of these, bacteria recovered from cefuroxime-injected eyes were resistant to cefuroxime in all cases (4/4), with Enterococcus comprising half of these. In eyes injected with moxifloxacin 0.1%, 6 out of 7 organisms were sensitive to moxifloxacin injected with 0.1 mL and in 1 eye injected with 1 mL. Streptococcus was the most common organism recovered (6/9) in moxifloxacin-injected eyes. Preoperative ACD and postoperative calculated ACV were higher in eyes injected with moxifloxacin. Endophthalmitis cases with positive cultures were generally related to organism resistance in cefuroxime eyes but to sensitive organisms in moxifloxacin eyes. Moxifloxacin doses may have been insufficient in eyes with larger ACV.
Identifiants
pubmed: 33571472
pii: S0002-9394(21)00069-6
doi: 10.1016/j.ajo.2021.02.007
pmc: PMC8184599
mid: NIHMS1674290
pii:
doi:
Substances chimiques
Anti-Bacterial Agents
0
Cefuroxime
O1R9FJ93ED
Moxifloxacin
U188XYD42P
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
166-172Subventions
Organisme : NEI NIH HHS
ID : R01 EY027329
Pays : United States
Organisme : NEI NIH HHS
ID : R21 EY022989
Pays : United States
Informations de copyright
Copyright © 2021 Elsevier Inc. All rights reserved.
Références
Ophthalmol Retina. 2021 Jun;5(6):503-510
pubmed: 32956857
Indian J Ophthalmol. 2017 Dec;65(12):1390-1395
pubmed: 29208819
J Cataract Refract Surg. 2008 Sep;34(9):1451-9
pubmed: 18721703
J Cataract Refract Surg. 2008 Jul;34(7):1114-20
pubmed: 18571078
Cornea. 2016 Dec;35(12):1631-1637
pubmed: 27490050
Clin Ophthalmol. 2014 Oct 24;8:2141-50
pubmed: 25368512
J Cataract Refract Surg. 2020 Mar;46(3):355-359
pubmed: 32050222
J Cataract Refract Surg. 2019 Mar;45(3):343-350
pubmed: 30691922
BMC Ophthalmol. 2015 Jul 08;15:72
pubmed: 26152124
Ophthalmology. 2016 Feb;123(2):287-294
pubmed: 26459998
Sci Rep. 2019 Jul 5;9(1):9745
pubmed: 31278356
J Cataract Refract Surg. 2018 Jan;44(1):28-33
pubmed: 29502614
J Cataract Refract Surg. 2016 Dec;42(12):1730-1741
pubmed: 28007104
Ophthalmology. 2014 Aug;121(8):1634-42
pubmed: 24702755
J Cataract Refract Surg. 2007 Jan;33(1):63-8
pubmed: 17189795
J Cataract Refract Surg. 2014 Nov;40(11):1872-8
pubmed: 25262563
Ophthalmology. 2016 Jul;123(7):1414-20
pubmed: 26992840
J Cataract Refract Surg. 2006 Mar;32(3):419-24
pubmed: 16631049
Cutan Ocul Toxicol. 2015;34(2):139-43
pubmed: 24964171
Clin Exp Ophthalmol. 2008 May;36(4):367-70
pubmed: 18700925
J Cataract Refract Surg. 2015 Nov;41(11):2410-6
pubmed: 26703490
J Cataract Refract Surg. 2007 Oct;33(10):1790-800
pubmed: 17889778
J Cataract Refract Surg. 2017 Jun;43(6):833-838
pubmed: 28732619
J Cataract Refract Surg. 2007 Jun;33(6):978-88
pubmed: 17531690
Am J Ophthalmol. 2005 Sep;140(3):497-504
pubmed: 16083841
J Cataract Refract Surg. 2019 Sep;45(9):1226-1233
pubmed: 31371152
J Cataract Refract Surg. 2013 Nov;39(11):1702-6
pubmed: 24054967
J Cataract Refract Surg. 2002 Jun;28(6):982-7
pubmed: 12036640
J Cataract Refract Surg. 2002 Jun;28(6):977-81
pubmed: 12036639
J Cataract Refract Surg. 2015 Jun;41(6):1300-5
pubmed: 26189384
JAMA Ophthalmol. 2015 Oct;133(10):1194-7
pubmed: 26226062
J Cataract Refract Surg. 2019 Oct;45(10):1498-1502
pubmed: 31444079
J Ophthalmol. 2016;2016:8656301
pubmed: 27688910